The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM‐I) regimen for intermediate‐grade non‐Hodgkin's lymphoma. Long term follow‐up in 51 patients

Ofer Shpilberg, Jacob Shif, Angela Chetrit, Bracha Ramot, Isaac Ben‐Bassat

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Background. Cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM‐I) is a second generation combination chemotherapy for intermediate‐grade non‐Hodgkin's lymphoma (NHL). Since the first report by Laurence et al. in 1982, only a few series were reported on the long term results of this regimen. Methods. In this prospective study, the clinical courses of 51 patients with intermediate‐grade NHL (F, G, or H according to the International Working Formulation grading criteria) with a median age of 65 years (range, 55–81), who were diagnosed between 1983 and 1992, are reported. Eligibility criteria included at least one full cycle of the regimen and no previous chemotherapy. Results. A mean of seven cycles (range, two to nine) with two escalations (range, zero to six) was administered. In a median follow‐up of 2.4 years (range, 0.5–10), 33 patients (65%) experienced complete remission. The projected 3‐year overall survival (OS) and progression free survival rates (PFS) were 58% and 77%, respectively, and the projected 5‐year OS and PFS were 52% and 72%, respectively. In only 2 patients (4%) were treatment‐related deaths observed, whereas nonfatal complications were more common. Patients in the low risk group, according to the international NHL prognostic index, had the best outcome. The mean percentage of projected dose intensity (DI) was 95% (range, 77–109), whereas no difference in DI was found between patients younger or older than 65 years. Conclusions. In a single center, COPBLAM‐I combination chemotherapy was safe and effective for patients older than 55 years with intermediate‐grade NHL.

Original languageEnglish
Pages (from-to)3029-3033
Number of pages5
JournalCancer
Volume74
Issue number11
DOIs
StatePublished - 1 Jan 1994
Externally publishedYes

Keywords

  • COPBLAM‐I
  • chemotherapy
  • dose intensity
  • non‐Hodgkin's lymphoma
  • prognostic index

Fingerprint

Dive into the research topics of 'The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM‐I) regimen for intermediate‐grade non‐Hodgkin's lymphoma. Long term follow‐up in 51 patients'. Together they form a unique fingerprint.

Cite this